ATR-Targeted Molecules Designed for CNS Penetration Set the Stage for Next-Generation TreatmentsVANCOUVER, British Columbia, ...

As recently as last month, the biotech had been setting out plans for a phase 3 trial of the combo treatment for later in ...

Merck KGaA’s ATR inhibitor cancer drug has been cleared for further clinical trials after it showed encouraging activity in a phase 1 study. Short for ataxia telangiectasia and Rad3-related ...

Their new study found that that stomach cancers could develop resistance to a new class of drugs called ATR inhibitors by switching off the activity of two key genes. The findings could pave the way ...

The firm will pause development of lunresertib and camonsertib while focusing on development of two newer programs.

Atriva Therapeutics is starting a phase 2 trial of its MEK inhibitor ATR-002 in patients with coronavirus infections, saying the drug could help prevent patients progressing to critical-stage ...

Senaparib is under clinical development by IMPACT Therapeutics and currently in Phase II for Solid Tumor. According to GlobalData, Phase II drugs for Solid Tumor have a 37% phase transition success ...

The advent of immunotherapy based on immune checkpoint inhibitors has improved the treatment of advanced hepatocellular ...